Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib + Gemcitabine in Recurrent Ovarian Cancer
NCT00096395Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2004
- Primary completion
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in ovarian epithelial cancer and primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Primary endpoint: Objective Tumor Response Rate up to 7 years. Started Sep 2004; status: completed.
02
Drugs
sorafenib
03
Conditions
ovarian epithelial cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00096395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00096395.